EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach

Michiel de Vries, Susanne Bonsmann, Jörg Pausch, Melanie Sumner, Alexander Birkmann, Holger Zimmermann, Dirk Kropeit

Clinical Pharmacology in Drug Development · 2024-07 · 13 (7) · 755-769

DOI: 10.1002/cpdd.1408 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 16.05.2024. Verfasst von Michiel de Vries und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molenpad ClinPharm Support, Weesp, The Netherlands. Hauptthemen laut MEDLINE: Drug Interactions, Cytochrome P-450 Enzyme System, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pritelivir is a novel viral helicase‐primase inhibitor active against herpes simplex virus. In vitro drug‐drug interaction studies indicated that pritelivir has the potential for clinically relevant interactions on the cytochrome P450 (CYP) enzymes 2C8, 2C9, 3A4, and 2B6, and intestinal uptake transporter organic anion transporting polypeptide (OATP) 2B1 and efflux transporter breast cancer resistance protein (BCRP). This was evaluated in 2 clinical trials. In 1 trial the substrates flurbiprofen (CYP2C9), bupropion (CYP2B6), and midazolam (CYP3A4) were administered simultaneously as part of the Geneva cocktail, while the substrate celiprolol (OAPT2B1) was administered separately. In another trial, the substrates repaglinide (CYP2C8) and rosuvastatin (BCRP) were administered separately. Exposure parameters of the substrates and their metabolites (flurbiprofen and bupropion only) were compared after administration with or without pritelivir under therapeutic concentrations. The results of these trials indicated that pritelivir has no clinically relevant effect on the exposure of substrates for the intestinal uptake transporter OATP2B1 and the CYP enzymes 3A4, 2B6, 2C9, and 2C8, and has a weak inhibitory effect on the intestinal efflux transporter BCRP. In summary, the results suggest that pritelivir has a low drug‐drug interaction potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsCytochrome P-450 Enzyme SystemATP Binding Cassette Transporter, Subfamily G, Member 2HumansFemaleMaleAdultBupropionSulfonamidesMiddle AgedRosuvastatin CalciumFlurbiprofenNeoplasm ProteinsOrganic Anion TransportersCarbamatesMidazolamYoung AdultPiperidines

Stichwörter der Autor:innen

Geneva cocktailcytochrome P450drug transportersdrug‐drug interactionpharmacokineticspritelivir

Substanzen

Cytochrome P-450 Enzyme SystemATP Binding Cassette Transporter, Subfamily G, Member 2ABCG2 protein, humanBupropionSulfonamidesRosuvastatin CalciumFlurbiprofenNeoplasm ProteinsOrganic Anion TransportersCarbamates

Autor:innen und Institutionen

  • Molenpad ClinPharm Support, Weesp, The Netherlands.
  • AiCuris Anti-infective Cures AG, Wuppertal, Germany.
  • Present affiliation: BioNTech SE, Mainz, Germany.

Zitieren

APA

de Vries, M., Bonsmann, S., Pausch, J., Sumner, M., Birkmann, A., Zimmermann, H., & Kropeit, D. (2024). Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach. Clinical Pharmacology in Drug Development, 13(7), 755-769. https://doi.org/10.1002/cpdd.1408

Vancouver

de Vries M, Bonsmann S, Pausch J, Sumner M, Birkmann A, Zimmermann H, et al. Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach. Clinical Pharmacology in Drug Development. 2024;13(7):755-769. doi:10.1002/cpdd.1408

BibTeX
@article{deVries2024,
  author = {de Vries, Michiel and Bonsmann, Susanne and Pausch, Jörg and Sumner, Melanie and Birkmann, Alexander and Zimmermann, Holger and Kropeit, Dirk},
  title = {Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {755--769},
  doi = {10.1002/cpdd.1408}
}
Kostenlos starten →